Case report| Volume 48, ISSUE 2, P167-168, July 15, 2000

H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients


      Background: Olanzapine is temporally associated, in a number of patients with schizophrenia, with weight gain. H2 antagonists, like nizatidine, have been shown to control appetite in overweight patients.
      Methods: A patient with olanzapine temporally associated weight gain was treated with nizatidine as “add-on” therapy.
      Results: Nizatidine treatment was associated with good control and subsequent reduction of weight after 4 to 5 weeks of therapy in a patient with repetitive episodes of weight gain during olanzapine treatment. Olanzapine was otherwise well tolerated and effective in controlling psychopathology.
      Conclusions: H2 antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia. Controlled studies are recommended to confirm this observation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Andersen T.
        • Rasmussen M.H.
        • Breum L.
        • Gotsche P.C.
        • Hilsted J.
        Antiobesity-effect of cimetidine suspension? Testing for success of blinding in a randomized cross-over trial.
        Acta Physiol Scand. 1992; 146: 60
        • Kinon B.J.
        • Basson B.
        • Szymanski K.
        • Tollefson G.D.
        Predictors of weight gain during olanzapine treatment.
        Eur Neuropsychopharmacol. 1998; 8: S220
        • Kinon B.J.
        • Basson B.R.
        • Tollefson G.D.
        Effect of long-term olanzapine treatment on weight change in schizophrenia.
        Schizophr Res. 2000; 41: 195-196
        • Mercer L.P.
        • Kelley D.S.
        • Humpries L.L.
        • Dunn J.D.
        Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats.
        J Nutr. 1994; 124: 1029-1036
        • Simansky K.J.
        Serotonergic control of the organization of feeding and satiety.
        Behav Brain Res. 1996; 73: 37-42
        • Singh K.
        • Singh P.I.
        Effect of cimetidine on weight gain in rats.
        Indian J Med Sci. 1995; 49: 257-260
        • Stoa-Birketvedt G.
        Cimetidine suspension reduces appetite and overweight in dieting subjects.
        Scand J Gastroenterol. 1992; 27: 70
        • Stoa-Birketvedt G.
        Effect of cimetidine suspension on appetite and weight in overweight subjects.
        Br Med J. 1993; 306: 1091-1093
        • Stoa-Birketvedt G.
        • Paus P.N.
        • Ganss R.
        • Florholmen J.
        Cimetidine reduces weight and improves metabolic control in type II diabetes mellitus.
        Diabetes. 1996; 45: 122A
        • Stoa-Birketvedt G.
        • Paus P.N.
        • Ganss R.
        • Ingebretsen O.C.
        • Florholmen J.
        Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes.
        Int J Obes Relat Metab Disord. 1998; 22: 1041-1045
        • Tecott L.H.
        • Sun L.M.
        • Akana S.F.
        • Strack A.M.
        • Lowenstein D.H.
        • Dallman M.F.
        • Julius D.
        Eating disorder and epilepsy in mice lacking 5-HT52C serotonin receptors.
        Nature. 1995; 374: 542-546
        • Tollefson G.D.
        • Beasley Jr, C.M.
        • Tran P.V.
        • Street J.S.
        • Krueger J.A.
        • Tamura R.N.
        • et al.
        Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders.
        Am J Psychiatry. 1997; 154: 457-465
        • Wirshing D.A.
        • Wirshing W.C.
        • Kysar L.
        • Berisford M.A.
        • Goldstein D.
        • Pashdag J.
        • et al.
        Novel antipsychotics.
        J Clin Psychiatry. 1999; 60: 358-363